BioLine Rx (BLRX) Stock Price, Quote, News & History | Benzinga

BioLine Rx Ltd (BLRX) Stock Price, Quote, News & History

BLRXNASDAQ

Trade with Public

Trade with Public

$2.70

-0.15-5.26%

At close: Aug 26, 5:00 PM EST

$2.75

0.051.85%

After Hours: 4:47 PM EST

Earnings: Q2 2026 Earnings in 5 days from now on Mon Aug 31st, before the market open

Conference Call: Conference call scheduled in 5 days at 8:30 AM

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

$2.91

Close

$2.70

Volume / Avg.

13.07K / 21.48K

Day Range

$2.65 - $3.03

52 Wk Range

2.15 - 4.56

Market Cap

$12.01M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

3.09%

Days to Cover

19.81

Recent BioLine RX Ltd News

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.

Vandana Singh

Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings

BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.

Avi Kapoor

3 Stocks Getting Rare Double Upgrades From Analysts

Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts’ expectations. However, that can become an opportunity for nimble investors with some cash on

MarketBeat

Dow Edges Higher; Dell Shares Fall After Q1 Results

Avi Kapoor

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-7.76M

Investing Cash Flow (TTM)

2.34M

Financing Cash Flow (TTM)

-1.75M

Free Cash Flow (TTM)

-7.80M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-7.17M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$4.81M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.85

PB Ratio (TTM)

0.75

Earnings Yield % (TTM)

0.00%

Earnings Yield % (FWD)

0.00%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.82

Company Debt

Total Debt

$7.84M

LT Debt

$3.36M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$445.00K

Total Cash

$2.50M

Debt to Equity

0.54

Issuance of Debt (TTM)

-$445.00K

Repayment of Debt (TTM)

-$4.94M

Key Statistics

Open

$2.91

Close

$2.70

Volume / Avg.

13.07K / 21.48K

Day Range

$2.65 - $3.03

52 Wk Range

2.15 - 4.56

Market Cap

$12.01M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

3.09%

Days to Cover

19.81

About

Sector

Health Care

Industry

Biotechnology

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for th...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy BioLine Rx (BLRX) stock?

A

You can purchase shares of BioLine Rx (NASDAQ:BLRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are BioLine Rx (BLRX) competitors?

A

Other companies in BioLine Rx’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for BioLine Rx (BLRX) stock?

A

BioLine Rx has a consensus price target of $19.00.

Q

What is the current price for BioLine Rx (BLRX)?

A

The stock price for BioLine Rx (NASDAQ: BLRX) is $2.75 last updated August 26, 2026 at 4:47 PM EDT.

Q

Does BioLine Rx (BLRX) pay a dividend?

A

There are no upcoming dividends for BioLine Rx.

Q

When is BioLine Rx (NASDAQ:BLRX) reporting earnings?

A

BioLine Rx does not have any upcoming earnings scheduled.

Q

Is BioLine Rx (BLRX) going to split?

A

There is no upcoming split for BioLine Rx.

Q

What sector and industry does BioLine Rx (BLRX) operate in?

A

BioLine Rx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.